uniQure (NASDAQ:QURE) Sees Strong Trading Volume After Better-Than-Expected Earnings

uniQure N.V. (NASDAQ:QURE) shares saw unusually-strong trading volume on Monday after the company announced better than expected quarterly earnings. Approximately 7,361,027 shares were traded during trading, an increase of 197% from the previous session’s volume of 2,476,159 shares.The stock last traded at $9.86 and had previously closed at $15.63.

The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported Q4 EPS of ($0.56) which beat the consensus loss (~$0.93) and posted revenue of $5.57M (above estimates), showing somewhat better near‑term operating results than expectations. uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Company published full 2025 results and a corporate update and said it held a Type A meeting with the FDA and is evaluating Phase III development considerations; uniQure plans to request a follow‑up Type B meeting in Q2 to clarify next steps. uniQure Announces 2025 Financial Results and Provides Recent Company Updates
• Neutral Sentiment: Market commentary pieces are reassessing uniQure’s valuation and outlook given the new regulatory focus; these analyses may increase trading volume and volatility as investors digest longer approval timelines. Assessing uniQure (QURE) After Sharp Share Price Slide And Gene Therapy Regulatory Focus
• Negative Sentiment: FDA told uniQure its AMT‑130 early‑to‑mid stage data are insufficient to support a marketing application and urged a new randomized trial for the Huntington’s disease gene therapy — a major setback that will likely delay approval, increase development cost and push out potential revenue. FDA tells UniQure study data insufficient for brain disorder therapy application
• Negative Sentiment: News outlets report the FDA decision sent QURE shares plunging (reports of ~40–45% premarket declines), reflecting investor concern about a materially longer path to commercialization for AMT‑130. uniQure Stock Plunges 40% After FDA Shocker
• Negative Sentiment: Multiple securities‑class action lawsuits and law‑firm solicitations allege disclosure failures tied to AMT‑130; ongoing litigation increases legal risk and could be a drag on investor sentiment and resources. uniQure N.V. Sued for Securities Law Violations

Analyst Upgrades and Downgrades

QURE has been the topic of several recent research reports. Wells Fargo & Company reduced their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Leerink Partners lowered their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Wolfe Research began coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, William Blair restated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $58.33.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 50,598 shares of company stock worth $1,248,588. 4.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new stake in shares of uniQure during the 3rd quarter valued at approximately $28,000. Torren Management LLC bought a new stake in uniQure during the fourth quarter valued at $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC acquired a new stake in uniQure during the fourth quarter worth about $48,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Down 36.5%

The stock has a market cap of $618.00 million, a P/E ratio of -2.26 and a beta of 0.66. The stock’s fifty day simple moving average is $23.46 and its 200-day simple moving average is $29.80. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.